Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Alcubierre N, Navarrete-Muñoz EM, Rubinat E, Falguera M, Valls J, Traveset A, Vilanova MB, Marsal JR, Hernandez M, Granado-Casas M, Martinez-Gonzalez D, Jurjo C, Franch-Nadal J, Vioque J, Mauricio D. Association of low oleic intake acid with diabetic retinopathy in type 2 diabetic patients: a case-control study. Nutr Metab (Lond). 2016 Jun 4;13(40). doi: 10.1186/s12986-016-0099-5
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Reed (Earnshaw) SR, Reed JH, Stuhldreher TJ. Transaction costs, taxes, and portfolio revision. J Contemp Bus Issue. 1997;5:40-8.
Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life-table analysis. J Chronic Dis. 1978 Jan 1;31(8):557-60. doi: 10.1016/0021-9681(78)90043-7
Rothman KJ. A pictorial representation of confounding in epidemiologic studies. J Chronic Dis. 1975 Feb;28(2):101-8.
Rothman KJ, Keller AZ. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis. 1972 Dec;25(12):711-6.